v3.22.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Total net revenue $ 117,169 $ 115,533
COST OF REVENUE 78,937 73,959
Total gross profit 38,232 41,574
Operating expenses:    
General and administrative 66,248 40,476
Research and development 7,713 2,456
Sales and marketing 16,299 13,749
Total operating expenses 90,260 56,681
Loss from operations (52,028) (15,107)
Interest (income) expense, net 1,301 1,177
Other (income) expenses, net (168) 4,854
Loss before taxes (53,161) (21,138)
Income tax (benefit) expense (3,753) 976
Net loss $ (49,408) $ (22,114)
NET LOSS PER SHARE    
Basic (in dollars per share) $ (0.40) $ (0.19)
Diluted (in dollars per share) $ (0.40) $ (0.19)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING    
Basic (in shares) 123,630 116,199
Diluted (in shares) 123,630 116,199
Clinical Services    
Total net revenue $ 98,791 $ 96,487
Total gross profit 33,524 34,922
Pharma Services    
Total net revenue 18,378 19,046
Total gross profit $ 4,708 $ 6,652

Source